Corcept Therapeutics (CORT) CDO exercises options, sells 20,000 shares

Rhea-AI Filing Summary

Corcept Therapeutics Chief Development Officer William Guyer reported an option exercise and share sale. On February 3, 2026, he exercised a stock option for 20,000 shares of common stock at $21.65 per share and then sold 20,000 shares at a weighted average price of $40.8667 under a prearranged Rule 10b5-1 trading plan adopted on November 27, 2024. After these transactions, he directly held 1,235 shares of common stock and 230,000 stock options that are fully exercisable.

Insider Trade Summary

Net Seller: 20,000 shares ($817,334)

Net Sell 3 txns

Insider Guyer William

Role Chief Development Officer

Sold 20,000 shs ($817K)

Type	Security	Shares	Price	Value
Exercise	Stock option (right to buy)	20,000	$0.00	--
Exercise	Common Stock	20,000	$21.65	$433K
Sale	Common Stock	20,000	$40.8667	$817K

Holdings After Transaction: Stock option (right to buy) — 230,000 shares (Direct); Common Stock — 21,235 shares (Direct)

Footnotes (1)

1. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $40.71 to $41.2804 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Fully exercisable.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guyer William

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/03/2026		M		20,000	A	$21.65	21,235	D
Common Stock	02/03/2026		S(1)		20,000	D	$40.8667(2)	1,235	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$21.65	02/03/2026		M			20,000	(3)	09/01/2031	Common Stock	20,000	$0.00	230,000	D

Explanation of Responses:

1. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.

2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $40.71 to $41.2804 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

3. Fully exercisable.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer.	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Corcept Therapeutics (CORT) report for William Guyer?

Corcept Therapeutics reported that Chief Development Officer William Guyer exercised options for 20,000 shares at $21.65 and sold 20,000 common shares at a weighted average price of $40.8667 on February 3, 2026, under a prearranged Rule 10b5-1 trading plan.

How many Corcept Therapeutics (CORT) shares did William Guyer sell and at what price?

William Guyer sold 20,000 shares of Corcept Therapeutics common stock at a weighted average price of $40.8667 per share. The filing notes actual sale prices ranged from $40.71 to $41.2804, with detailed breakdowns available from the issuer upon request.

What stock options did William Guyer exercise in the Corcept Therapeutics (CORT) Form 4?

William Guyer exercised a stock option covering 20,000 shares of Corcept Therapeutics common stock at an exercise price of $21.65 per share on February 3, 2026. After the transaction, he beneficially owned 230,000 stock options that are reported as fully exercisable.

How many Corcept Therapeutics (CORT) shares does William Guyer own after the reported transactions?

Following the February 3, 2026 transactions, William Guyer directly owned 1,235 shares of Corcept Therapeutics common stock. In addition, he held 230,000 stock options, giving him further potential exposure to the company’s equity beyond his remaining direct share position.

Was William Guyer’s Corcept Therapeutics (CORT) share sale part of a trading plan?

Yes. The filing states the sale transaction was made under a Rule 10b5-1 trading plan that William Guyer adopted on November 27, 2024. Such plans allow executives to pre-schedule trades, helping separate routine portfolio management from day-to-day market or company developments.

What role does William Guyer hold at Corcept Therapeutics (CORT) according to the Form 4?

According to the Form 4, William Guyer serves as Chief Development Officer of Corcept Therapeutics. His officer status means his trades in company stock must be reported to the SEC, providing transparency into his equity transactions and resulting ownership levels for public investors.